← Back to Screener
Monopar Therapeutics Inc. Common Stock (MNPR)
Price$57.70
Favorite Metrics
Price vs S&P 500 (26W)-45.24%
Price vs S&P 500 (4W)-6.49%
Market Capitalization$387.54M
All Metrics
Book Value / Share (Quarterly)$20.60
P/TBV (Annual)0.46x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.82
Price vs S&P 500 (YTD)-13.96%
EPS (TTM)$-1.82
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.82
EPS (Annual)$-1.85
ROI (Annual)-9.95%
Cash / Share (Quarterly)$20.98
ROA (Last FY)-9.75%
EBITD / Share (TTM)$-2.25
ROE (5Y Avg)-68.19%
Cash Flow / Share (Annual)$-1.82
P/B Ratio2.81x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$-1
ROA (TTM)-13.93%
EPS Incl Extra (Annual)$-1.85
Current Ratio (Annual)51.35x
Quick Ratio (Quarterly)51.35x
3-Month Avg Trading Volume0.25M
52-Week Price Return54.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.47
52-Week High$105.00
EPS Excl Extra (Annual)$-1.85
Tangible BV CAGR (5Y)0.96%
26-Week Price Return-41.25%
Quick Ratio (Annual)51.35x
13-Week Price Return-10.95%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)51.35x
Enterprise Value$325.708
Book Value / Share Growth (5Y)71.95%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$20.98
3-Month Return Std Dev57.32%
Net Income / Employee (TTM)$-1
ROE (Last FY)-9.95%
EPS Basic Excl Extra (Annual)$-1.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.82
ROI (TTM)-14.24%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.78
Price vs S&P 500 (52W)24.64%
Year-to-Date Return-11.32%
5-Day Price Return-0.02%
EPS Normalized (Annual)$-1.85
ROA (5Y Avg)-54.77%
Month-to-Date Return5.69%
Cash Flow / Share (TTM)$-0.40
EBITD / Share (Annual)$-2.25
ROI (5Y Avg)-68.19%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.82
P/TBV (Quarterly)0.69x
P/B Ratio (Annual)3.17x
Book Value / Share (Annual)$20.60
Price vs S&P 500 (13W)-11.64%
Beta1.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-14.24%
52-Week Low$28.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MNPRMonopar Therapeutics Inc. Common Stock | — | — | — | — | $57.70 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapeutics with a diversified pipeline spanning multiple development stages. The company's programs include Validive for chemoradiotherapy-induced oral mucositis in oropharyngeal cancer, camsirubicin for soft tissue sarcoma, the preclinical antibody MNPR-101 for cancers and severe COVID-19, and the early-stage analog MNPR-202 for multiple cancer types.